




Roche SARS-CoV-2 Rapid Antigen Testing Portfolio & Emerging Virus Variants

Roche has conducted sequence analyses in collaboration with our partner, SD Biosensor, as well as wet testing (conducted by SD Biosensor) to evaluate the potential impact of the SARS-CoV-2 variants, including the SARS-CoV-2 variants of concern - **Alpha** (B.1.1.7 lineage); **Beta** (B.1.351 lineage), **Gamma** (P.1 lineage), **Delta** (B.1.617.2 lineage) and **Omicron** (B.1.1.529 lineage) - on the SARS-CoV-2 Rapid Antigen Test, SARS-CoV-2 Rapid Antigen Test Nasal, and the SARS-CoV-2 Antigen Self Test Nasal.



No impact of the following virus variants has been observed on the Roche SARS-CoV-2 Rapid Antigen Testing Portfolio:

WHO label	Lineage	WHO Classification	Country first reported
Alpha	B.1.1.7	VOC	UK
Beta	B.1.351	VOC	South Africa
Gamma	P.1	VOC	Brazil
Delta	B.1.617.2	VOC	India
Delta	AY.1		India
Delta	AY.2		India
Delta	AY.3		India
Omicron	BA.1 (sub lineage B.1.1.529)	VOC	Multiple countries
Omicron	BA.2 (sub lineage B.1.1.529)		Multiple countries
Lambda	C.37	VOI	Peru
Mu	B.1.621	VOI	Colombia
NA	B.1.640	VUM	Multiple countries
NA	C.1.2	VUM	South Africa

WHO label	Lineage	WHO Classification	Country first reported
Epsilon	B.1.427	NA	USA
Epsilon	B.1.429	NA	USA
Eta	B.1.525	NA	Multiple countries
Iota	B.1.526	NA	USA
Kappa	B.1.617.1	NA	Multiple countries
Zeta	P.2	NA	Brazil
Theta	P.3	NA	Philippines
NA	A.23.1	NA	UK
NA	AT.1	NA	Russia
NA	B	NA	China
NA	B.1.616	NA	France
NA	C.36	NA	Egypt

VOC: Variant of Concern, VOI: Variant of Interest, VUM: Variant Under Monitoring

As emerging virus variants are identified, we commit to continuously monitor them independently and in collaboration with our partner, SD Biosensor.

References

- 1) SD Biosensor, Analytical Study (in-silico testing): In-silico Analysis for the impact of SARS-CoV-2 Variants_Rev.09
- 2) SD Biosensor, Analytical Study (wet testing): Wet testing of recombinant N protein sequences of SARS-CoV-2 variants_Rev.04